MHRA Approves Icotrokinra Hydrochloride: New Plaque Psoriasis Drug

• The MHRA has approved icotrokinra hydrochloride (Icotyde) for moderate to severe plaque psoriasis in adults and adolescents aged 12 and over.
• This new oral psoriasis drug, developed by Janssen-Cilag Limited, is taken as a 200mg tablet once daily.
• Approval was based on four Phase 3 clinical trials involving 2,500 participants, demonstrating efficacy by week 16.
• Icotyde works by selectively blocking the IL-23 receptor, which is involved in inflammatory responses.
• The MHRA will continue to closely monitor the drug's safety, encouraging side effect reporting via the Yellow Card scheme.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for icotrokinra hydrochloride, marketed as Icotyde, marking a significant development for individuals suffering from moderate to severe plaque psoriasis in the United Kingdom.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for icotrokinra hydrochloride, marketed as Icotyde, marking a significant development for individuals suffering from moderate to severe plaque psoriasis in the United Kingdom. This new oral psoriasis drug UK is specifically authorized for adults and adolescents aged 12 years and older, provided they weigh at least 40 kg and are deemed suitable candidates for systemic therapy. The authorization, issued to Janssen-Cilag Limited, introduces an additional therapeutic pathway for managing this chronic inflammatory skin condition.

Plaque psoriasis is characterized by red, scaly, and often intensely itchy or painful patches that can manifest across various body parts, including the scalp, genitals, hands, feet, and even the nails. The debilitating nature of the condition underscores the importance of new treatment modalities like the MHRA approves icotrokinra hydrochloride, offering patients and healthcare providers more choices in their treatment regimens. This approval represents a forward step in addressing the unmet needs within the moderate severe plaque psoriasis treatment landscape.

The decision by the Medicines Healthcare products Regulatory Agency to approve Icotyde was underpinned by robust clinical evidence derived from four comprehensive Phase 3 trials. These studies collectively involved 2,500 participants diagnosed with moderate to severe plaque psoriasis, a cohort that included 72 adolescents aged between 12 and under 18 years, each weighing a minimum of 40 kg. The findings from all four trials consistently demonstrated the efficacy of icotrokinra hydrochloride in treating the condition when compared against a placebo group, with significant results observed by the 16-week mark.

Icotrokinra hydrochloride operates through a targeted mechanism of action, selectively binding to and blocking the IL-23 receptor. Interleukin-23 (IL-23) is a cytokine known to play a crucial role in inflammatory and immune responses, contributing directly to the chronic inflammation characteristic of immune-mediated diseases such as psoriasis. Administered as a 200mg tablet taken once daily, this oral medication offers a convenient treatment approach. Patients are advised to adhere strictly to the instructions provided in the Patient Information Leaflet and to consult their doctor or pharmacist for any queries regarding their prescribed treatment.

The formal authorization for icotrokinra hydrochloride (Icotyde) was officially granted on October 23, 2026, to Janssen-Cilag Limited. As the primary regulatory body for all medicines and medical devices within the UK, the MHRA ensures that all its decisions are grounded in robust, fact-based judgments, prioritizing that the benefits of any approved treatment demonstrably outweigh its potential risks. This commitment extends to the continuous monitoring of newly authorized medicines.

Following the Icotyde plaque psoriasis approval UK, the MHRA has affirmed its intention to closely monitor the safety profile of icotrokinra hydrochloride. Both patients and healthcare professionals are strongly encouraged to report any suspected side effects through the established Yellow Card scheme. Further detailed information, including the Summary of Product Characteristics and Patient Information Leaflets, will be made publicly available on the MHRA Products website within seven days of the approval date, providing comprehensive guidance for prescribers and users alike.

Pharmaceutical companies, particularly Janssen-Cilag and its competitors, must integrate this new drug approval into their market access strategies, regulatory compliance frameworks, and pharmacovigilance reporting protocols in the UK. Lawyers advising these entities should be prepared to address implications related to market competition, prescribing guidelines, and ongoing safety monitoring.

Source: Original reporting via UK government regulatory announcement